4 stories found
French spirits giant Pernod Ricard and Jack Daniel's maker Brown-Forman are reportedly in merger talks, a move that analysts are now weighing in on as both companies battle a sales slump and slowing demand.
Pharmaceutical giant Novartis has announced its intention to purchase Excellergy, a developer of allergy drugs, in a deal valued at up to $2 billion, expanding its portfolio in the allergy treatment market.
Pharmaceutical company Novartis is expanding its allergy medication business with the acquisition of the unlisted US biotech firm Excellergy in a deal valued at up to $2 billion, marking its second multi-billion dollar acquisition in a week and betting on a next-generation allergy treatment.
Novartis has confirmed its intention to acquire Excellergy, an allergy-drug developer, in a deal valued at up to $2 billion, with the Wall Street Journal providing further details and confirmation on the acquisition.